Bioanalytical method validation for the simultaneous determination of ceftazidime and avibactam in rat plasma. (January 2016)

• Record Type: Journal Article
• Authors: Beaudoin, Marie-Eve; Gangl, Eric T
• Is Part Of: Bioanalysis. Volume 8:Number 2(2016)
• Page Start: 111
• Page End: 122
• Publication Date: 2016-01
• Subjects: antibacterial resistance -- avibactam -- ceftazidime -- cephalosporins -- combination therapy; Drugs -- Analysis -- Periodicals; 615.19005
• DOI: 10.4155/bio.15.233
• Languages: English
• ISSNs: 1757-6180

Abstract

Background: Combination therapies have gained momentum in the disease management strategies of various indications. While it is challenging and more time consuming to develop a combined analytical method, the strategy of simultaneous analysis offers significant advantages in terms of efficiency and cost–effectiveness.Results: Due to a significant difference in efficacious dose for ceftazidime and avibactam, the calibration ranges validated in this paper were set to 0.05–50 μg/ml for ceftazidime and 0.005–5.0 μg/ml for avibactam. Interday results of ceftazidime were within 8% for accuracy and 9% for precision and within 9% for both accuracy and precision of avibactam.Conclusion: A sensitive and selective LC–MS/MS method was developed for the simultaneous quantification of ceftazidime and avibactam in rat plasma.